<DOC>
	<DOCNO>NCT01435772</DOCNO>
	<brief_summary>This Phase 2 open-label , multiple dose study BMN 701 administer IV infusion every 2 week ( qow ) patient late-onset Pompe disease .</brief_summary>
	<brief_title>Extension Study Patients Who Have Participated BMN 701 Study</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>Have complete prior BMN 701 clinical development study ; Have provide write informed consent nature study explain prior performance studyrelated procedure . Minors may participate long provide write assent nature study explain parent , legal guardian provide write informed consent , prior performance studyrelated procedure ; Have diagnose lateonset Pompe Disease , base entry criterion prior BMN 701 study ; If sexually active , willing use 2 know effective method contraception Screening 4 month last dose studydrug ; If female , consider childbearing potential , least 2 year postmenopausal , tubal ligation least 1 year prior screening , total hysterectomy ; If female , childbearing potential , negative pregnancy test Screening Period Baseline visit , willing additional pregnancy test study ; Have ability comply protocol requirement , opinion Investigator . Have receive experimental approve therapy Pompe disease , BMN 701 , subsequent completion BMN 701 study prior entry POM002 ; Have receive , anticipated receive , investigational medication , BMN 701 , within 30 day prior first dose studydrug ; Are breastfeed screen plan become pregnant ( self partner ) time study ; Have medical condition extenuate circumstance , opinion Investigator , might compromise patient 's ability comply protocol requirement compromise patient 's well safety .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>